title: Subconjunctival bevacizumab for iris neovascularisation - Authors' reply.
authors.affiliation: W K Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA. Electronic address: rajeshr@umich.edu.
authors.forename: Rajesh C
authors.initials: RC
authors.lastname: Rao
authors.affiliation: Herzig Eye Institute, Toronto, ON, Canada.
authors.forename: Netan
authors.initials: N
authors.lastname: Choudhry
authors.affiliation: Washington University School of Medicine, St Louis, MO, USA.
authors.forename: Rajendra S
authors.initials: RS
authors.lastname: Apte
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A